Literature DB >> 19092296

Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.

F Cetani1, E Pardi, E Ambrogini, C Banti, P Viacava, S Borsari, J P Bilezikian, A Pinchera, C Marcocci.   

Abstract

HRPT2 and parafibromin studies improved the diagnostic accuracy in two patients with primary hyperparathyroidism (PHPT) referred to us after surgery, in whom the clinical data were at variance with the pathological diagnosis of adenoma and carcinoma, respectively. Patients were referred to us after parathyroidectomy. Patient #1 had had a 1.5-cm tumor easily removed with a histological diagnosis of parathyroid carcinoma and normocalcemia for 2 years. Re-examination of the histology showed no cardinal signs of parathyroid cancer. Patient #2, with severe PHPT, had had the removal of a 3.5-cm tumor described histologically as adenoma. Ten years later PHPT recurred and persisted despite removal of two mildly enlarged parathyroid glands that were histologically normal. Re-review of the initial histology showed a trabecular pattern, fibrous bands, and atypical mitoses, suggesting an atypical adenoma. Because of the suspicion that case #1 could be an atypical adenoma and case #2 a carcinoma further molecular studies were performed. No HRPT2 and parafibromin abnormalities were identified in patient #1, strongly indicating a benign lesion. In patient #2, an HRPT2 germline mutation was found (E115X in exon 4) and associated with no parafibromin staining. These data, together with the clinical features, supported the suspicion of a parathyroid carcinoma that was confirmed by histological examination of further slides of the tumor, showing capsular and vascular invasion. A lung 1.5-cm nodule detected by computed tomography was excised. Histology showed a metastasis of parathyroid carcinoma. HRPT2 gene studies improved the diagnostic accuracy in 2 parathyroid tumors that are of uncertain type.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092296      PMCID: PMC5319599          DOI: 10.1007/BF03346439

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

Review 1.  Clinical review 122: Parathyroid carcinoma.

Authors:  E Shane
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance.

Authors:  Vito Guarnieri; Alfredo Scillitani; Lucia Anna Muscarella; Claudia Battista; Nazzareno Bonfitto; Michele Bisceglia; Salvatore Minisola; Maria Lucia Mascia; Leonardo D'Agruma; David E C Cole
Journal:  J Clin Endocrinol Metab       Date:  2006-05-23       Impact factor: 5.958

3.  Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.

Authors:  Anthony J Gill; Adele Clarkson; Oliver Gimm; Juliane Keil; Henning Dralle; Viive M Howell; Deborah J Marsh
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

4.  Parathyroid carcinoma. A study of 70 cases.

Authors:  A Schantz; B Castleman
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

5.  Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.

Authors:  Thomas G Kelly; Trisha M Shattuck; Miguel Reyes-Mugica; Andrew F Stewart; William F Simonds; Robert Udelsman; Andrew Arnold; Thomas O Carpenter
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

6.  Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors.

Authors:  Filomena Cetani; Elena Pardi; Simona Borsari; Paolo Viacava; Giada Dipollina; Luisella Cianferotti; Elena Ambrogini; Elisabetta Gazzerro; Giacomo Colussi; Piero Berti; Paolo Miccoli; Aldo Pinchera; Claudio Marcocci
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

7.  Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.

Authors:  Min-Han Tan; Carl Morrison; Pengfei Wang; Ximing Yang; Carola J Haven; Chun Zhang; Ping Zhao; Maria S Tretiakova; Eeva Korpi-Hyovalti; John R Burgess; Khee Chee Soo; Wei-Keat Cheah; Brian Cao; James Resau; Hans Morreau; Bin Tean Teh
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.

Authors:  V M Howell; C J Haven; K Kahnoski; S K Khoo; D Petillo; J Chen; G J Fleuren; B G Robinson; L W Delbridge; J Philips; A E Nelson; U Krause; K Hammje; H Dralle; C Hoang-Vu; O Gimm; D J Marsh; H Morreau; B T Teh
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

9.  Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.

Authors:  C C Juhlin; A Villablanca; K Sandelin; F Haglund; J Nordenström; L Forsberg; R Bränström; T Obara; A Arnold; C Larsson; A Höög
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

10.  Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma.

Authors:  V L Cryns; A Thor; H J Xu; S X Hu; M E Wierman; A L Vickery; W F Benedict; A Arnold
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

View more
  7 in total

1.  Hyperparathyroidism-jaw tumor syndrome: Results of operative management.

Authors:  Amit Mehta; Dhaval Patel; Avi Rosenberg; Myriem Boufraqech; Ryan J Ellis; Naris Nilubol; Martha M Quezado; Stephen J Marx; William F Simonds; Electron Kebebew
Journal:  Surgery       Date:  2014-10-16       Impact factor: 3.982

Review 2.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

Review 3.  Update on parathyroid carcinoma.

Authors:  F Cetani; E Pardi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2016-03-21       Impact factor: 4.256

4.  Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.

Authors:  Maurizio Iacobone; Giulia Masi; Luisa Barzon; Andrea Porzionato; Veronica Macchi; Francesco Antonio Ciarleglio; Giorgio Palù; Raffaele De Caro; Giovanni Viel; Gennaro Favia
Journal:  Langenbecks Arch Surg       Date:  2009-06-16       Impact factor: 3.445

Review 5.  Challenges and pitfalls in the management of parathyroid carcinoma: 17-year follow-up of a case and review of the literature.

Authors:  Janneke E Witteveen; Harm R Haak; Job Kievit; Hans Morreau; Johannes A Romijn; Neveen A T Hamdy
Journal:  Horm Cancer       Date:  2010-11-19       Impact factor: 3.869

6.  Management and Outcome of Parathyroid Carcinoma-Induced Primary Hyperparathyroidism: A Single-Centre Experience.

Authors:  Loredana De Pasquale; Antonio Mario Bulfamante; Giovanni Felisati; Luca Castellani; Giorgio Ghilardi; Alberto Maria Saibene
Journal:  Int J Endocrinol       Date:  2021-10-07       Impact factor: 3.257

Review 7.  Parathyroid carcinoma.

Authors:  Claudio Marcocci; Filomena Cetani; Mishaela R Rubin; Shonni J Silverberg; Aldo Pinchera; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.